MGNX MacroGenics, Inc.: Wutah pendapatan triwulanan

The QoQ revenue growth rate demonstrates business dynamics, where the value -75.00 captures this metric. MacroGenics, Inc. (MGNX) revenues are based on the sale of the drug Margenza and partner payments within the metastatic breast cancer therapy segment. R&D stability is ensured by diversified protein synthesis maintaining the cold chain, while competitiveness is supported by the creation of targeted antibodies and the receipt of stable royalties.
Rincian analitis lan laporan data perusahaan MacroGenics (MGNX)

This metric calculates the percentage change in revenue for the current quarter compared to the same period last year, measuring business scaling rates and market expansion. For MacroGenics, Inc. (MGNX), this quarterly revenue growth indicator reflects the commercial efficiency of the DART platform implementation, demonstrating how successfully bispecific antibodies are being monetized within the cancer therapy segment.